<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PROMAZINE HYDROCHLORIDE</span><br/>(proe'ma-zeen)<br/><span class="topboxtradename">Prozine-50, </span><span class="topboxtradename">Sparine<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">psychotherapeutic</span>; <span class="classification">antipsychotic</span>; <span class="classification">phenothiazine</span><br/><b>Prototype: </b>Chlorpromazine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg tablets; 25 mg/mL, 50 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Derivative of phenothiazine. Compared with chlorpromazine has weak antipsychotic activity and extrapyramidal effects occur
         less frequently. Thought to block the postsynaptic dopamine receptors in the brain, with a higher affinity for D<sub>1</sub> over D<sub>2</sub> dopamine receptors.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antipsychotic drugs are sometimes called neuroleptics (or tranquilizers) because they tend to reduce initiative and interest
         in the environment, decrease displays of emotions or affect, suppress spontaneous movements and complex behavior, and decrease
         psychotic symptoms.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Manifestations of psychotic disorders and for reducing agitation and paranoia associated with alcohol withdrawal.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to phenothiazines; myelosuppression; CNS depression; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Prostatic hypertrophy; cardiovascular or liver disease; paralytic ileus; xerostomia; angle closure glaucoma; persons exposed
         to extremes in temperature or to organophosphorous insecticides; convulsive disorders.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Psychotic Disorders</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IM</span> 10200 mg q46h up to 1000 mg/d<br/><span class="rdage">Adolescent:</span> <span class="rdroute">PO/IM</span> <i>&gt;12 y</i>, 1025 mg q46h<br/><br/><span class="indicationtitle">Dementia Behavior</span><br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO/IM</span> Start with 25 mg 12 times/d, may increase q47d in divided doses (max: 500 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Use oral route whenever possible. Reserve parenteral administration for acutely disturbed or uncooperative patients or those
            who cannot tolerate oral preparation.
         </li>
<li>Give 1 h before or 2 h after antacid; absorption is inhibited by antacids.</li>
<li>Dilute the concentrate immediately before administration with fruit juice, chocolate-flavored drinks, carbonated drinks, or
            soup (for best taste, 10 mL of diluent for each 25 mg of drug). Avoid coffee or tea ingestion at or near medication times.
            Explain dosage and dilution to patient if drug is to be self-administered.
         </li>
<li>Avoid contact of liquid preparations with skin.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Make IM injection deep into upper outer quadrant of buttock. Carefully aspirate before injecting drug slowly. Tissue irritation
            can occur if given SC. Intraarterial injection can cause arterial or arteriolar spasm and consequent impairment of local circulation.
            Rotate injection sites.
         </li>
<li>Store at 15°30° C (59°86° F) in light-resistant container unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Drowsiness, orthostatic hypotension,</span> syncope. <span class="typehead">Special Senses:</span> Blurred vision, photosensitivity. <span class="typehead">GI:</span> Constipation, xerostomia. <span class="typehead">CNS:</span> Extrapyramidal effects, tardive dyskinesia, epileptic seizures in susceptible individuals, leukopenia, <span class="speceff-life">agranulocytosis</span> (rare). <span class="typehead">CV:</span> Hypotension, sinus tachycardia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b>, <span class="classification">cns depressants</span> increases CNS depression; <b>phenobarbital</b> increases metabolism; <span class="classification">general anesthetics</span> increase excitation and hypotension; antagonizes antihypertensive action of <b>guanethidine;</b> <b>phenylpropanolamine</b> poses possibility of sudden death; <span class="classification">tricyclic antidepressants</span> intensify hypotensive and anticholinergic effects; <span class="classification">anticonvulsants</span> decrease seizure thresholdmay need to increase anticonvulsant dose. <span class="typehead">Herbal:</span> <b>Kava-kava</b> may increase risk and severity of dystonic reactions. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Variable, absorbed from GI tract. <span class="typehead">Metabolism:</span> Metabolized in liver. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP and pulse before administration and between doses. Keep patient recumbent for about 1 h after IM dose is given
            because incidence of postural hypotension and drowsiness is particularly high after parenteral administration.
         </li>
<li>Encourage adequate fluid intake as prophylaxis for constipation and xerostomia. The depressed patient may not seek help for
            either symptom or for urinary retention.
         </li>
<li>Report symptoms suggesting agranulocytosis promptly (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Make position changes slowly, particularly from lying down to upright positions. Dizziness or faintness may occur on arising.</li>
<li>Avoid alcohol during therapy.</li>
<li>Do not spill oral solutions on hands or clothing; wash exposed skin well with soap and water. Drug may cause contact dermatitis.</li>
<li>Be aware that promazine may color urine pink to red to reddish brown.</li>
<li>Do not take OTC drugs without physician approval.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>